Minatx Company

Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver diseases. Our initial product candidate will achieve clinical proof of concept in 2017.
Technology: Gene therapy
Industry: Personalized Medicine
Headquarters: London, England, United Kingdom
Founded Date: 2008
Employees Number: 1-10
Funding Status: N/A

Visit Website
info@minatx.com
@mina_tx
Register and Claim Ownership